Wyeth's transdermal nitroglycerin
FDA conditionally approved Wyeth's transdermal delivery system, trademarked Deponit 5 and Deponit 10, May 6. The product is available in dosages of 5 mg/24 hours and 10 mg/24 hours. Wyeth is the fifth firm to enter the transdermal nitroglycerin market. Bolar, Ciba-Geigy, Searle and Key Pharmaceuticals already market transdermal nitroglycerin.
You may also be interested in...
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.